Industry‐sponsored meal payments are associated with prescriptions and Medicare expenditures on brand‐name colchicine in the United States

Abstract

AbstractAimTo investigate the association between industry‐sponsored meal payments and the prescribing patterns of brand‐name colchicines, namely Colcrys and Mitigare, among Medicare beneficiaries in the United States from 2014 to 2021.MethodsThis cross‐sectional study utilized data from the Open Payments Database and Medicare Part D covering the years 2014 to 2021. The study included 54 836 physicians who submitted more than 10 colchicine claims. Exposure was defined as the receipt of one or more industry‐sponsored meals from the manufacturers of Colcrys or Mitigare. The primary outcomes included the likelihood of prescribing Colcrys and Mitigare, as well as the associated number of claims and Medicare expenditures.ResultsAmong 54 836 eligible physicians, 44.9% received meal payments from the Colcrys manufacturer, and 8.0% from the Mitigare manufacturer, over the eight‐year study period. The average meal payment value was $14.9 for Colcrys and $15.1 for Mitigare. The receipt of meal payments was significantly associated with an increased likelihood of prescribing Colcrys (odds ratio: 1.24 [95% CI: 1.21–1.27], p < .001) and Mitigare (odds ratio: 3.54 [95% CI: 2.98–4.20], p < .001). Each additional meal payment corresponded with a significant increase in Medicare expenditures: $55.4 (95% CI: $48.3–$62.5, p < .001) for Colcrys and $153.7 (95% CI: $17.7–$289.6, p = .03) for Mitigare. These associations remained consistent across different specialties and genders.ConclusionThis study reveals that receipt of meal payments from manufacturers of brand‐name colchicine was significantly associated with an increased rate of prescriptions for these brand‐name drugs, leading to higher Medicare expenditures in the United States.